Pharmacokinetics, Safety, and Tolerability of SYN-020
Study Details
Study Description
Brief Summary
This is a Phase 1, single-center, open-label, single ascending dose study to assess the PK, safety, and tolerability of SYN-020 delayed release capsules administered orally to healthy adult male and female subjects with a BMI of 18.5 to 27 kg/m2. Up to 36 subjects will participate, in each of up to 6 sequential cohorts. Single doses of 5, 15, 45, and 150 mg SYN-020 are planned in Cohorts 1 through 4, respectively. Cohorts 5 and 6, if enrolled, will receive doses that were well tolerated in an earlier cohort to determine the effect of BMI and/or a high-fat meal on the SYN-020 PK profile.
For each cohort, eligible subjects will be admitted to the clinic on Day -1, and receive study drug in the morning of Day 1. For PK analysis, blood and feces will be collected before dosing and for up to 96 hours (blood) or 120 hours (feces) after dosing. Subjects will be discharged from the clinic after the End of Study procedures are completed on Day 6.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
Intestinal alkaline phosphatase (IAP) is a naturally occurring enzyme produced by the small intestine in all mammals, including humans, and is considered essential for promoting normal gastrointestinal (GI) function and maintaining proper gut homeostasis, as well as appearing to play a pivotal role in the mediation of inflammation.
SYN-020 is a recombinant bovine IAP isotype II being developed by Synthetic Biologics, Inc. to reduce the cumulative GI toxicity and inflammation that can be associated with repeat administration of radiation in patients with cancer.
This is a Phase 1, single-center, open-label, single ascending dose study to assess the PK, safety, and tolerability of SYN-020 delayed release capsules administered orally to healthy adult male and female subjects with a BMI of 18.5 to 27 kg/m2. Up to 36 subjects will participate, with 6 subjects (approximately equal numbers of male and females) in each of up to 6 sequential cohorts. Single doses of 5, 15, 45, and 150 mg SYN-020 are planned in Cohorts 1 through 4, respectively. Cohorts 5 and 6, if enrolled, will receive doses that were well tolerated in an earlier cohort to determine the effect of BMI and/or a high-fat meal on the SYN-020 PK profile, and will be described fully in a protocol amendment.
For each cohort, eligible subjects will be admitted to the clinical research unit (CRU) on Day -1, and subjects who remain eligible will, after a minimum 10-hour overnight fast, receive study drug in the morning of Day 1. For PK analysis, blood and feces will be collected before dosing and for up to 96 hours (blood) or 120 hours (feces) after dosing. Subjects will be discharged from the CRU after the End of Study (EOS) procedures are completed on Day 6.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: SYN-020, 5 mg 6 subjects to receive a single 5 mg dose of SYN-020 |
Drug: SYN-020 delayed release capsule
SYN-020, is an opaque, white, size 3 HPMC capsule for oral administration containing enteric-coated, delayed-release pellets.
Other Names:
|
| Experimental: SYN-020, 15 mg 6 subjects to receive a single 15 mg dose of SYN-020 |
Drug: SYN-020 delayed release capsule
SYN-020, is an opaque, white, size 3 HPMC capsule for oral administration containing enteric-coated, delayed-release pellets.
Other Names:
|
| Experimental: SYN-020, 45 mg 6 subjects to receive a single 45 mg dose of SYN-020 |
Drug: SYN-020 delayed release capsule
SYN-020, is an opaque, white, size 3 HPMC capsule for oral administration containing enteric-coated, delayed-release pellets.
Other Names:
|
| Experimental: SYN-020, 150 mg 6 subjects to receive a single 150 mg dose of SYN-020 |
Drug: SYN-020 delayed release capsule
SYN-020, is an opaque, white, size 3 HPMC capsule for oral administration containing enteric-coated, delayed-release pellets.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- SYN-020 systemic absorption [Daily Day 1 through Day 5]
Analysis of SYN-020 level present in blood
- SYN-020 presence in feces [Daily Day -1 through Day 6]
Analysis of SYN-020 level present in feces
Secondary Outcome Measures
- Percentage of Participants with Changes in Clinical Laboratory Testing [Day -1, Day 2, Day 6]
Hematology, clinical chemistry, urinalysis, virus serology, drug screen, alcohol screen, pregnancy test, postmenopausal screen
- Number of Participants With Changes in Physical exam [Day 1 and Day 6]
Complete and abbreviated physical examinations will be performed
- Number of Participants with Changes in Vital Signs [Daily Day -1 through Day 6]
Blood pressure, pulse rate, respiratory rate, oral temperature
- Number of Participants with Changes in Electrocardiograms [Day -1, Day 1, Day 2, Day 6]
12-lead ECG, P-wave, QRS-complex, QT-interval
- Immunogenicity testing [Day 1, Day 6]
Measurement of anti-drug antibodies by ELISA
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Subject is able to read, write, and comprehend English at a sufficient level to understand study related materials, has provided written informed consent before any study-related procedure was performed, and is willing and able to comply with all testing and study requirements.
-
Subject is a healthy male or female, aged 18 through 50 years, inclusive.
-
Subject does not use any tobacco or nicotine product (eg, cigarette, pipe, e-cigarette, vape) and has not used any tobacco or nicotine product for at least 2 months before Day -1.
-
Subject has a BMI of 18.5 to 27 kg/m2 for initial cohorts or, for exploratory cohorts, ≥ 27.1 kg/m2. For Cohorts 1 through 4, if insufficient subjects are available to meet this criterion, subjects with a BMI up to 29 kg/m2 may be included with written authorization from the Sponsor.
-
Subject is healthy based on physical examination, clinical laboratory tests, 12-lead ECG, and vital signs.
-
Subject is willing to minimize the risk of inducing pregnancy from the time of signing the informed consent form (ICF) to at least either 90 days (males) or 30 days (females) after the study drug dose.
-
If female, subject has a negative serum pregnancy test at Screening and on Day -1 (CRU admission).
-
Subject usually has at least 1 bowel movement a day based on self-reporting.
Exclusion Criteria:
-
Subject has a history or the presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, vascular, metabolic, collagen, or psychiatric disease or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the subject or the validity of the study results.
-
Subject has any known malabsorption syndrome or history of gastrointestinal surgery that could compromise the study objectives.
-
Subject has used any medication (prescription or non-prescription) or herbal supplement, other than prescription hormone replacement therapy (eg, thyroid, testosterone, estrogen) or contraception methods described in Inclusion Criterion #6, within 21 days before Day -1.
-
Subject is pregnant, breastfeeding, or not using a medically accepted method of contraception.
-
Subject is unable to abstain from artificial sweeteners (eg, aspartame, acesulfame potassium, advantame, saccharin, stevia, and sucralose) from CRU admission to the end of study participation.
-
Subject has a positive urine drug or alcohol test at Screening or CRU admission OR has a history of drug/alcohol abuse within 12 months before Screening.
-
Subject has donated more than 500 mL blood during the 3-month period before Day -1.
-
Subject has known intolerance of study drug/ingredients.
-
In the judgment of the Investigator, subject has any factor (eg, other treatment) that could invalidate the study result.
-
Subject is currently enrolled in another clinical study or has received an investigational drug or device within 30 days or within a time period consistent with a washout period of 5 half-lives before signing the ICF, whichever is longer.
-
Subject has already participated in this study.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Spaulding Clinical Research LLC | West Bend | Wisconsin | United States | 53095 |
Sponsors and Collaborators
- Synthetic Biologics Inc.
- Spaulding Clinical Research LLC
Investigators
- Principal Investigator: Carlos Sanabria, MD, Spaulding Clinical Research LLC
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SB-1-020-001